| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Program expenses-IMM1104 | NaN | -23,946,023 | NaN |
| Program expenses-Atebimetinib IMM1104 | -4,055,258 | NaN | NaN |
| Program expenses-IMM6415 | NaN | -4,097,651 | NaN |
| Program expenses-Envometinib IMM6415 | -4,345 | NaN | NaN |
| Program expenses-Other Programs | 2,074,128 | -6,509,028 | NaN |
| Non-program expenses | 3,207,656 | -7,464,608 | NaN |
| Employee-related costs | 9,148,153 | -25,539,568 | NaN |
| Stock-based compensation expense | 3,036,615 | -7,890,500 | NaN |
| Depreciation and amortization | 167,226 | -418,416 | NaN |
| Other segment items | 695,777 | 1,940,894 | NaN |
| Net loss | 30,983,993 | -14,964,876 | -29,480,012 |
| Depreciation and amortization expense | -167,226 | 78,840 | 169,788 |
| Reduction in carrying amount of right-of-use assets | -163,900 | 87,274 | 168,386 |
| Intangible asset amortization | -14,633 | 7,317 | 14,633 |
| Stock-based compensation expense | -3,036,615 | 1,456,080 | 3,217,210 |
| Net accretion of discount on marketable securities | 404,723 | 0 | 0 |
| Loss on disposal of fixed assets | NaN | 0 | NaN |
| Prepaid expenses and other current assets | 3,085,087 | 168,824 | -2,072,921 |
| Other assets | 797,414 | -348,790 | -454,058 |
| Accounts payable | 384,635 | -974,893 | 500,679 |
| Accrued expenses | -6,687,037 | 2,366,906 | -458,170 |
| Lease liabilities | 152,307 | -84,230 | -162,298 |
| Other liabilities | -93,747 | -129,619 | -23,957 |
| Net cash used in operating activities | 17,070,553 | -11,977,235 | -23,526,762 |
| Purchases of property and equipment | 61,614 | 7,255 | 11,061 |
| Purchases of marketable securities | 71,990,845 | 0 | NaN |
| Maturities of marketable securities | 9,000,000 | 0 | 0 |
| Net cash used in investing activities | -63,052,459 | -7,255 | -11,061 |
| Proceeds from exercise of stock options | -128,265 | 136,645 | 2,055 |
| Proceeds from issuance of common stock under employee stock purchase plan | -251,585 | 288,018 | 133,892 |
| Proceeds from issuance of common stock under at-the-market offering, net of issuance costs | -15,020,046 | 15,020,046 | NaN |
| Proceeds from issuance of common stock under at-the-market offering, net of issuance costs-Warrant | NaN | 24,998,919 | NaN |
| Proceeds from issuance of common stock under at-the-market offering, net of issuance costs-Public Offering | NaN | 164,500,006 | NaN |
| Proceeds from issuance of common stock under at-the-market offering, net of offering expenses | NaN | NaN | 13,676,667 |
| Proceeds from issuance of common stock through private placement with aventis inc | NaN | 25,000,000 | NaN |
| Payment of offering and placement costs | NaN | 3,074,898 | 64,013 |
| Net cash provided by financing activities | -226,759,910 | 213,192,069 | 13,748,601 |
| Net decrease in cash and cash equivalents | -272,741,816 | 201,207,579 | -9,789,222 |
| Cash and cash equivalents at beginning of period | 227,563,077 | 36,144,720 | NaN |
| Cash and cash equivalents at end of period | 47,321,566 | 227,563,077 | NaN |
Immuneering Corp (IMRX)
Immuneering Corp (IMRX)